---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-26-000019"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:07:08.180579+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions appoints John D. Fowler, Jr. to board of directors effective March 1, 2026

## Summary
- Fowler appointed as Class II director and will serve on the Audit and Finance Committee.
- Receives initial RSU grant valued at $270,000 vesting in three equal annual installments.
- Annual compensation: $70,000 cash retainer, $15,000 committee fee, $270,000 equity award (prorated first year).
- Chairman Zsolt Harsanyi states Fowler's experience will support the company's ongoing turnaround and transformation.
- Fowler brings 30+ years in healthcare and finance, including senior roles at Wells Fargo, Deutsche Bank, and JPMorgan.

## SEC filing metadata
- accession: 0001367644-26-000019
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000019/0001367644-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000019/ebs-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-26-000019
- JSON: https://secwatch.observer/filing/0001367644-26-000019.json
- Plain text: https://secwatch.observer/filing/0001367644-26-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.